1. Home
  2. GRFS vs CGNX Comparison

GRFS vs CGNX Comparison

Compare GRFS & CGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • CGNX
  • Stock Information
  • Founded
  • GRFS 1940
  • CGNX 1981
  • Country
  • GRFS Spain
  • CGNX United States
  • Employees
  • GRFS N/A
  • CGNX N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • CGNX Industrial Machinery/Components
  • Sector
  • GRFS Health Care
  • CGNX Industrials
  • Exchange
  • GRFS Nasdaq
  • CGNX Nasdaq
  • Market Cap
  • GRFS 6.6B
  • CGNX 7.4B
  • IPO Year
  • GRFS 2006
  • CGNX 1989
  • Fundamental
  • Price
  • GRFS $9.61
  • CGNX $45.64
  • Analyst Decision
  • GRFS Hold
  • CGNX Buy
  • Analyst Count
  • GRFS 1
  • CGNX 11
  • Target Price
  • GRFS $10.30
  • CGNX $43.18
  • AVG Volume (30 Days)
  • GRFS 550.4K
  • CGNX 1.9M
  • Earning Date
  • GRFS 01-01-0001
  • CGNX 10-29-2025
  • Dividend Yield
  • GRFS 1.47%
  • CGNX 0.70%
  • EPS Growth
  • GRFS 132.60
  • CGNX 59.92
  • EPS
  • GRFS 0.53
  • CGNX 0.72
  • Revenue
  • GRFS $8,744,226,659.00
  • CGNX $929,555,000.00
  • Revenue This Year
  • GRFS $5.61
  • CGNX $7.79
  • Revenue Next Year
  • GRFS $6.70
  • CGNX $9.56
  • P/E Ratio
  • GRFS $24.41
  • CGNX $63.97
  • Revenue Growth
  • GRFS 9.32
  • CGNX 10.14
  • 52 Week Low
  • GRFS $6.19
  • CGNX $22.67
  • 52 Week High
  • GRFS $11.14
  • CGNX $47.52
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 41.63
  • CGNX 53.86
  • Support Level
  • GRFS $9.56
  • CGNX $44.52
  • Resistance Level
  • GRFS $10.23
  • CGNX $47.23
  • Average True Range (ATR)
  • GRFS 0.18
  • CGNX 1.18
  • MACD
  • GRFS -0.01
  • CGNX -0.14
  • Stochastic Oscillator
  • GRFS 11.85
  • CGNX 31.81

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About CGNX Cognex Corporation

Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.

Share on Social Networks: